Maze Therapeutics has a total of 21 patents globally, out of which no patents have been granted. Of these 21 patents, more than 95% patents are active. Canada is where Maze Therapeutics has filed the maximum number of patents, followed by Australia and United States of America. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Maze Therapeutics.
Maze Therapeutics was founded in the year 2018. The Company is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines.
Do read about some of the most popular patents of Maze Therapeutics which have been covered by us in this article and also you can find Maze Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Maze Therapeutics patent portfolio.
How many patents does the founder and the CEO of Maze Therapeutics have?
The founder Charles Homcy has 6 patents and CEO Jason Coloma has 0 patent.
How many patents does Maze Therapeutics have?
Maze Therapeutics has a total of 21 patents globally. These patents belong to 5 unique patent families. Out of 21 patents, 20 patents are active.
How Many Patents did Maze Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||Maze Therapeutics Applications Filed||Maze Therapeutics Patents Granted|
How many Maze Therapeutics patents are Alive/Dead?
How Many Patents did Maze Therapeutics File in Different Countries?
Countries in which Maze Therapeutics Filed Patents
|United States Of America||2|
|Hong Kong (S.A.R.)||1|
Where are Research Centres of Maze Therapeutics Patents Located?
The Research Centre for all the Maze Therapeutics patents is the United States of America.
List of Maze Therapeutics Patents
|Maze Therapeutics Patents||Title|
|US20230265096A1||Apol1 Inhibitors And Methods Of Use|
|US20230104740A1||Inhibitors Of Glycogen Synthase 1 (Gys1) And Methods Of Use Thereof|
|EP4100527A2||Compositions And Methods For Treating Neurodegenerative Diseases|
|WO2023141432A2||Apol1 Inhibitors And Methods Of Use|
|WO2022216759A1||Compositions And Methods For Treating Tdp-43 Proteinopathy|
|WO2022198196A1||Inhibitors Of Glycogen Synthase 1 (Gys1) And Methods Of Use Thereof|
|WO2022178315A1||Apol1 Inhibitors And Methods Of Use|
|WO2022170146A1||Vectors Comprising Stuffer Polynucleotide Sequences|
|CA3179181A1||Inhibitors Of Glycogen Synthase 1 (Gys1) And Methods Of Use Thereof|
|CA3179178A1||Apol1 Inhibitors And Methods Of Use|
|CA3206272A1||Vectors Comprising Stuffer Polynucleotide Sequences|
|CA3166978A1||Compositions And Methods For Treating Neurodegenerative Diseases|
|AU2022218196A1||Vectors Comprising Stuffer Polynucleotide Sequences|
|AU2021215934A1||Compositions And Methods For Treating Neurodegenerative Diseases|
|HK40084683A||Compositions And Methods For Treating Neurodegenerative Diseases|
|IL295284A||Compositions And Methods For Treating Neurodegenerative Diseases|
|JP2023512836A||Compositions And Methods For Treating Neurodegenerative Diseases|
|KR1020220139344A||Compositions And Methods For Treating Neurological Diseases|
|SG11202251849QA||Compositions And Methods For Treating Neurodegenerative Diseases|
|TW202302570A||Inhibitors Of Glycogen Synthase 1 (Gys1) And Methods Of Use Thereof|
|WO2021159008A3||Compositions And Methods For Treating Neurodegenerative Diseases|
What are Maze Therapeutics key innovation segments?
What Technologies are Covered by Maze Therapeutics?
The chart below distributes patents filed by Maze Therapeutics